Schiff base complexes of copper and zinc as potential anti-colitic compounds

Elaine M. Conner, John Reglinski, W. Ewen Smith, I. Jack Zeitlin

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The design, synthesis and activity of polymodal compounds for the treatment of inflammatory bowel disease are reported. The compounds, being based on a metal-Schiff base motif, are designed to degrade during intestinal transit to release the bioactive components in the gut. The compounds have been developed sequential with the biomodal compounds combining copper or zinc with a salicylaldehyde adduct. These compounds were tested in a formalin induced colonic inflammation model in BK:A mice. From these studies a trimodal compound based on a zinc Schiff base analogue of Sulfosalazine were designed. This was tested against a trinitrobenzenesulfonic acid (TNB) induced colitic model in Wistar rats. The use of two models allows us to test our compounds in both an acute and a chronic model. The trimodal compound reported is observed to provide anticolitic properties in the chronic TNB induced colitis model commensurate with that of SASP. However, the design of trimodal compound still has the capacity for further development. This the platform reported may offer a route into compounds which can markedly outperform the anti-colitic properties of SASP.
LanguageEnglish
Pages423-439
Number of pages17
JournalBioMetals
Volume30
Issue number3
Early online date19 Apr 2017
DOIs
Publication statusPublished - 30 Jun 2017

Fingerprint

Trinitrobenzenesulfonic Acid
Schiff Bases
Zinc
Copper
copper
zinc
Colitis
Inflammatory Bowel Diseases
Formaldehyde
Wistar Rats
Metals
Inflammation
Zinc compounds
inflammatory bowel disease
Copper compounds
acids
colitis
formalin
Acids
digestive system

Keywords

  • inflammatory bowel disease
  • metal-Schiff base
  • colitis

Cite this

Conner, E. M., Reglinski, J., Smith, W. E., & Zeitlin, I. J. (2017). Schiff base complexes of copper and zinc as potential anti-colitic compounds. BioMetals, 30(3), 423-439. https://doi.org/10.1007/s10534-017-0016-z
Conner, Elaine M. ; Reglinski, John ; Smith, W. Ewen ; Zeitlin, I. Jack. / Schiff base complexes of copper and zinc as potential anti-colitic compounds. In: BioMetals. 2017 ; Vol. 30, No. 3. pp. 423-439.
@article{e2dd3a7b927b4c5b810d8e1bdedbcc33,
title = "Schiff base complexes of copper and zinc as potential anti-colitic compounds",
abstract = "The design, synthesis and activity of polymodal compounds for the treatment of inflammatory bowel disease are reported. The compounds, being based on a metal-Schiff base motif, are designed to degrade during intestinal transit to release the bioactive components in the gut. The compounds have been developed sequential with the biomodal compounds combining copper or zinc with a salicylaldehyde adduct. These compounds were tested in a formalin induced colonic inflammation model in BK:A mice. From these studies a trimodal compound based on a zinc Schiff base analogue of Sulfosalazine were designed. This was tested against a trinitrobenzenesulfonic acid (TNB) induced colitic model in Wistar rats. The use of two models allows us to test our compounds in both an acute and a chronic model. The trimodal compound reported is observed to provide anticolitic properties in the chronic TNB induced colitis model commensurate with that of SASP. However, the design of trimodal compound still has the capacity for further development. This the platform reported may offer a route into compounds which can markedly outperform the anti-colitic properties of SASP.",
keywords = "inflammatory bowel disease, metal-Schiff base, colitis",
author = "Conner, {Elaine M.} and John Reglinski and Smith, {W. Ewen} and Zeitlin, {I. Jack}",
year = "2017",
month = "6",
day = "30",
doi = "10.1007/s10534-017-0016-z",
language = "English",
volume = "30",
pages = "423--439",
journal = "BioMetals",
issn = "0966-0844",
number = "3",

}

Conner, EM, Reglinski, J, Smith, WE & Zeitlin, IJ 2017, 'Schiff base complexes of copper and zinc as potential anti-colitic compounds' BioMetals, vol. 30, no. 3, pp. 423-439. https://doi.org/10.1007/s10534-017-0016-z

Schiff base complexes of copper and zinc as potential anti-colitic compounds. / Conner, Elaine M.; Reglinski, John; Smith, W. Ewen; Zeitlin, I. Jack.

In: BioMetals, Vol. 30, No. 3, 30.06.2017, p. 423-439.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Schiff base complexes of copper and zinc as potential anti-colitic compounds

AU - Conner, Elaine M.

AU - Reglinski, John

AU - Smith, W. Ewen

AU - Zeitlin, I. Jack

PY - 2017/6/30

Y1 - 2017/6/30

N2 - The design, synthesis and activity of polymodal compounds for the treatment of inflammatory bowel disease are reported. The compounds, being based on a metal-Schiff base motif, are designed to degrade during intestinal transit to release the bioactive components in the gut. The compounds have been developed sequential with the biomodal compounds combining copper or zinc with a salicylaldehyde adduct. These compounds were tested in a formalin induced colonic inflammation model in BK:A mice. From these studies a trimodal compound based on a zinc Schiff base analogue of Sulfosalazine were designed. This was tested against a trinitrobenzenesulfonic acid (TNB) induced colitic model in Wistar rats. The use of two models allows us to test our compounds in both an acute and a chronic model. The trimodal compound reported is observed to provide anticolitic properties in the chronic TNB induced colitis model commensurate with that of SASP. However, the design of trimodal compound still has the capacity for further development. This the platform reported may offer a route into compounds which can markedly outperform the anti-colitic properties of SASP.

AB - The design, synthesis and activity of polymodal compounds for the treatment of inflammatory bowel disease are reported. The compounds, being based on a metal-Schiff base motif, are designed to degrade during intestinal transit to release the bioactive components in the gut. The compounds have been developed sequential with the biomodal compounds combining copper or zinc with a salicylaldehyde adduct. These compounds were tested in a formalin induced colonic inflammation model in BK:A mice. From these studies a trimodal compound based on a zinc Schiff base analogue of Sulfosalazine were designed. This was tested against a trinitrobenzenesulfonic acid (TNB) induced colitic model in Wistar rats. The use of two models allows us to test our compounds in both an acute and a chronic model. The trimodal compound reported is observed to provide anticolitic properties in the chronic TNB induced colitis model commensurate with that of SASP. However, the design of trimodal compound still has the capacity for further development. This the platform reported may offer a route into compounds which can markedly outperform the anti-colitic properties of SASP.

KW - inflammatory bowel disease

KW - metal-Schiff base

KW - colitis

UR - https://link.springer.com/journal/volumesAndIssues/10534

U2 - 10.1007/s10534-017-0016-z

DO - 10.1007/s10534-017-0016-z

M3 - Article

VL - 30

SP - 423

EP - 439

JO - BioMetals

T2 - BioMetals

JF - BioMetals

SN - 0966-0844

IS - 3

ER -